Genomenon, Inc., a pioneering force in genomic data analysis, is headquartered in the United States. Founded in 2013, the company has rapidly established itself within the biotechnology industry, focusing on innovative solutions for genomic research and clinical applications. Genomenon’s flagship product, the Mastermind Genomic Search Engine, uniquely integrates genomic data with clinical insights, enabling researchers and healthcare professionals to make informed decisions. This powerful tool streamlines the process of variant interpretation, significantly enhancing the efficiency of genomic studies. With a strong market position, Genomenon has garnered recognition for its contributions to precision medicine, helping to bridge the gap between genomic information and actionable insights. The company continues to expand its operational reach, supporting advancements in personalised healthcare across various regions.
How does Genomenon, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Computer Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Genomenon, Inc.'s score of 17 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Genomenon, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Genomenon may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives at this time. As such, the company appears to be in the early stages of addressing its climate impact, with no inherited emissions data from a parent or related organisation.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Genomenon, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
